Trimethoprim-Sulfamethoxazole-Induced Pancytopenia: A Case Report.

Area of Science:

• Hematology
• Pharmacology
• Clinical Medicine

Background:

• Pancytopenia involves a reduction in all three myeloid cell lines, often triggered by autoimmune diseases, medications, or other factors.
• Determining the cause of pancytopenia requires laboratory tests, peripheral blood smear analysis, and comprehensive patient history and physical examination.
• Trimethoprim-sulfamethoxazole (TMP/SMX) is a known, albeit rare, cause of pancytopenia, with limited existing literature explaining its mechanism.

Observation:

• A severe case of pancytopenia was observed.
• The patient presented with symptoms indicative of pancytopenia.
• The condition was linked to the use of Trimethoprim-sulfamethoxazole (TMP/SMX).

Findings:

• The patient's pancytopenia rapidly improved upon discontinuation of TMP/SMX.
• Platelet levels were successfully repleted, contributing to the resolution.
• This case highlights a severe presentation of drug-induced pancytopenia.

Implications:

• This case underscores the importance of considering TMP/SMX as a potential cause of pancytopenia in clinical practice.
• Prompt recognition and drug cessation are crucial for managing TMP/SMX-induced pancytopenia.
• Further research is warranted to fully elucidate the mechanisms behind TMP/SMX-induced hematologic toxicity.